一项元分析比较了质子束疗法与碳离子放射治疗之间的疗效和安全性
Jeong Yun Jang1, Kangpyo Kim1, Miao-Fen Chen2
1Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Cancer medicine
|February 24, 2024
概括
质子束疗法 (PBT) 和碳离子放射疗法 (CIRT) 在元分析中显示了可比的瘤结果和不良事件. 这一系统性审查发现,对于大多数癌症治疗结果,PBT和CIRT之间没有显著差异.
科学领域:
- 在瘤学瘤学.
- 辐射疗法 辐射疗法
- 医学物理 医学物理
背景情况:
- 先进的放射治疗技术,如质子束疗法 (PBT) 和碳离子放射治疗 (CIRT) 越来越多地用于癌症治疗.
- 对PBT和CIRT的直接临床比较是有限的,需要综合证据.
研究的目的:
- 系统地审查和元分析现有临床证据,比较PBT和CIRT的结果.
- 评估PBT和CIRT之间的瘤结果 (局部控制,无进展生存,整体生存) 和不良事件.
主要方法:
- 对比PBT和CIRT临床结果的研究进行系统的文献搜索.
- 纳入标准要求报告瘤结果或不良事件.
- 18篇文章的元分析和子组分析,涉及1857名患者 (947名PBT,910名CIRT).
主要成果:
- 聚合分析显示,PBT和CIRT之间的无进展生存 (PFS) 或总生存 (OS) 没有显著差异.
- 在总人口中观察到有利于CIRT的局部控制 (LC) 的显著差异 (HR 0.690,p=0.031).
- 亚组分析显示大多数结果没有显著差异,除了非头部和部部位的LC外. 不良事件发生率相似 (OR 1.097).
结论:
- 质子束疗法 (PBT) 和碳离子放射疗法 (CIRT) 具有可比的疗效和安全性.
- 这些发现支持使用PBT和CIRT作为可行的治疗选择,具有类似的瘤结果和毒性.
- 进一步的研究可能会探索特定的患者群体或瘤类型,其中一种模式可能提供优势.
更多相关视频
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
2.8K
05:18Immunofluorescence Imaging of DNA Damage and Repair Foci in Human Colon Cancer Cells
Published on: June 9, 2020
11.1K
相关概念视频
Cancer Survival Analysis
346
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
346
Hazard Ratio
122
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
122
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Comparing the Survival Analysis of Two or More Groups
186
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
186
